A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors - Trial NCT05996445
Access comprehensive clinical trial information for NCT05996445 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xencor, Inc. and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 210 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xencor, Inc.
Timeline & Enrollment
Phase 1
Jul 28, 2023
Sep 30, 2030
Primary Outcome
Incidence of dose-limiting toxicities (DLTs),Incidence and severity of treatment emergent adverse events (TEAEs)
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
 intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in
 subjects with advanced solid tumors and to identify the recommended dose regimen that is safe
 and biologically effective for XmAb662.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05996445
Non-Device Trial